XTALPi and HKU's ABIC Forge Strategic Partnership to Commercialize Hard-Tech Biomedical Innovations

On November 27, XtalPi and the Advanced Biomedical Instrumentation Centre (ABIC) at the University of Hong Kong (HKU) signed a Memorandum of Understanding today. Both parties will work together to advance the hard-tech achievements obtained by ABIC’s research teams in Hong Kong and globally, promoting research collaboration and commercial applications.

XtalPi, as a globally leading innovative platform enterprise, combines its unique technological advantages in quantum physics, artificial intelligence (AI), and automated robotics to focus on the discovery and iterative upgrading of innovative drugs and materials. The scientist team at ABIC is composed of interdisciplinary experts from the University of Hong Kong and researchers from Harvard University's School of Engineering and Applied Sciences, possessing abundant research achievements in the field of biomedical instruments.

According to the agreement, XtalPi will evaluate the commercialization potential of ABIC's technology assets and intellectual property portfolio, lead and promote the commercial implementation of specific ABIC technologies, and share its experience and knowledge in product development and the transformation of scientific research achievements with ABIC. This collaboration fully reflects XtalPi's long-term efforts and determination to establish itself in the Guangdong-Hong Kong-Macao Greater Bay Area, advance the transformation of cutting-edge technologies through extensive cooperation and R&D investment, and implement commercially impactful solutions for the industry.

ABIC will incorporate XtalPi's professional insights and experience accumulated in global business development, actively promoting win-win cooperation between research and commercial organizations. The memorandum of cooperation with XtalPi will bring together ABIC's top engineers and scientists to jointly develop competitive next-generation diagnostic and therapeutic technologies, bringing positive impact to the development of the healthcare industry in Asia and even globally.

Editor: Muyan

Disclaimer: This article is a reprint from PharmNet. The images and text are the original property of the author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.